Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study Source: Eur Respir J 2015; 46: 783-794 Year: 2015
A phase II trial of lipoplatin-gemcitabine in patients with advanced NSCLC: preliminary results Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Paclitaxel/carboplatin vs paclitaxel/carboplatin/etoposide as first line treatment in SCLC. A phase III randomized trial Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
Topotecan in combination with carboplatin and etoposide as first line treatment in SCLC patients: a phase I/II study – final results Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol Source: Eur Respir J 2016; 48: 320-330 Year: 2016
Pattern of drug resistance among patients who fail Cat II regimen and patients who fail standard treatment: is there any difference? Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
A multicenter randomized phase III-trial with carboplatin (C) and paclitaxel (P) in advanced NSCLC: preliminary results of dose adjusted weekly schedule, compared to standard regime (q3w) Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
Randomized phase II study of adjuvant cisplatin/docetaxel (Cis-Doc) or cisplatin/vinorelbine (Cis-VRB) in patients (pts) with resected stage IB-II NSCLC: interim analysis Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies Source: Eur Respir J, 58 (3) 2004233; 10.1183/13993003.04233-2020 Year: 2021
Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Design of phase II, randomized, placebo-controlled study of loratadine associate with rapamycin in patients with lymphangioleiomyomatosis (LAM) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Comparing different initial doses of afatinib used as first-line treatment for patients with stage IV lung adenocarcinoma Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006
Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013